Surveillance of glaucoma medical therapy in a Glasgow teaching hospital: 26 years' experience

Rahman, Mamun Q.; Montgomery, Donald; Lazaridou, Marie-Noëlle

doi:10.1136/bjo.2008.151522

Cited by 15 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although definitions of persistency may differ slightly between studies, these findings are similar to those found in large, retrospective studies in the literature 13–16. This may be due to much lower rates of adverse effects with latanoprost than other medications as we have reported in a previous study 11. Latanoprost continues to be the most prescribed drug in our clinic, as can be seen in figure 2B.…”

Section: Discussionsupporting

confidence: 56%

See 1 more Smart Citation

Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database

Rahman

Abeysinghe²,

Kelly

et al. 2011

British Journal of Ophthalmology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 56%

“…We have previously described, in this journal, a large and unique computerised database established at the glaucoma clinic at Glasgow Royal Infirmary, with data now spanning 27 years 11. We now present our findings on treatment persistence in patients on glaucoma medical therapy.…”

Section: Introductionmentioning

confidence: 99%

Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database

Rahman

Abeysinghe²,

Kelly

et al. 2011

British Journal of Ophthalmology

View full text Add to dashboard Cite

“…Fewer than 3% of subjects discontinued the FC due to an ocular adverse event. The tolerability of an ocular hypotensive agent is important given the negative impact of ocular adverse events on patient continuation with therapy [24,25]. …”

Section: Discussionmentioning

confidence: 99%

Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: A prospective, observational, noninterventional study

Schwenn

Heckmann²,

Guzy

et al. 2010

BMC Ophthalmol

View full text Add to dashboard Cite

BackgroundProspective, observational studies that enroll large numbers of patients with few exclusion criteria may better reflect actual ongoing clinical experience than randomized clinical trials. Our purpose was to obtain efficacy and safety information from a cohort of subjects exposed to latanoprost/timolol fixed combination (FC) for ≥18 months using a prospective, observational design.MethodsIn all, 577 office-based ophthalmologists in Germany switched 2339 patients with glaucoma or ocular hypertension to latanoprost/timolol FC for medical reasons. Follow-up visits were scheduled for every 6 months over 24 months; physicians followed usual care routines. Intraocular pressure (IOP), visual field status, optic nerve head findings, and adverse events were recorded. Efficacy parameters were evaluated for the per protocol (PP) population; the safety population included subjects receiving ≥1 drop of FC. Physicians rated efficacy, tolerability, and subject compliance at month 24.ResultsOf the 2339 subjects switched to latanoprost/timolol FC (safety population), the primary reasons for switching were inadequate IOP reduction (78.2%) and desire to simplify treatment with once-daily dosing (29.4%; multiple reasons possible). In all, 1317 (56.3%) subjects completed the study, and 1028 (44.0%) were included in the PP population. Most discontinuations were due to loss to follow-up. Change in mean IOP from baseline to month 6 was -4.0 ± 4.31 mmHg, a reduction that was maintained throughout (P < 0.05 for change at all time points). By investigator assessments, optic disc parameters and visual field were stable over 24 months, and there was no relationship between IOP reduction over 24 months and development of a visual field defect. More than 90% of physicians rated latanoprost/timolol FC as "very good" or "good" for efficacy (PP population), tolerability, and compliance. The FC was safe and well tolerated. No change in iris color was reported by most subjects (83.1%) at month 24.ConclusionsOver 24 months, latanoprost/timolol FC effectively lowers IOP levels and is well tolerated in patients with glaucoma or ocular hypertension who change from their previous ocular hypotensive therapy for medical reasons. Investigator assessments found optic disc parameters and visual field to be stable throughout 24 months of follow-up.

show abstract

“…We have previously described, in this journal, a large and unique computerised database established at the glaucoma clinic at Glasgow Royal Infirmary, with data now spanning 27 years 8 9. We now present our findings on the total direct healthcare-related costs for glaucoma management in a population of patients for whom we have complete lifetime data.…”

Section: Introductionmentioning

confidence: 99%